Patent Application
20210353673
The present invention relates to isolated mammalian CD11b+/PIEZO-1+ macrophage cells, neutrophil cells, and/or an isolated exosome as secreted by said cells, pharmaceutical compositions comprising said cells and/or exosomes, as well as uses thereof.
Mechanical aspects of the cellular environment can influence cell function, and in this context hydrogels can serve as an instructive matrix.
Living cells of higher organisms reside in an environment that is mechanically and biologically well-defined by an extracellular matrix (ECM). Structural and mechanical aspects of the ECM, such as stiffness and topography, can have a substantial influence on different cell functions like cell growth or differentiation of the cells. In this context hydrogels can serve as such an “instructive” matrix.
U.S. 2014-0147407 discloses a matrix comprising a modified primary hydroxyl groups containing polysaccharide comprising repeating disaccharide units wherein in at least part of the disaccharide units the primary hydroxyl group is replaced by functional groups selected from halide groups or groups comprising sulfur or phosphorus atoms, like e.g. sulfate groups, sulfonate groups, phosphonate groups and phosphate groups. The matrix as disclosed can be used e.g. as a food additive, material for surgery implants, in controlled drug release systems, as lubricant for industrial purposes, for conditioning of liquids, in biomedical device coatings, as excipients in drug delivery formulations, in cell encapsulation and in the area of tissue engineering and regenerative medicine.
The organization of cells into tissue-like structures involves a complex interplay between soluble signals and those originating from the ECM.
Vascularization is critical for the survival of cells and necessary for the transport of signaling molecules to aid in regeneration. Vasculogenesis, as it pertains to in vitro studies, is the formation of lumens from dispersed endothelial cells (ECs), and it differs from angiogenesis where ECs sprout from an existing blood vessel or an EC monolayer.
To identify the factors that influence EC organization, several in vitro models have been established, including collagen gel, fibrin gel, and matrigel. These studies have revealed that arginine-glycine-aspartic acid (RGD) integrin binding sequence and soluble signals such as vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2) are essential and that the mechanical aspects of the gel impact the formation of EC networks. Nevertheless, the factors that impact the organization of multiple ECs in freestanding tubular structures are not fully understood.
Jaipersad A S et al. (in: Jaipersad A S et al. The role of monocytes in angiogenesis and atherosclerosis. J Am Coll Cardiol. 2014 Jan. 7-14; 63(1):1-11) disclose that the two known mechanisms resulting in the formation of new vessels are local ischemia and inflammation. Blood monocytes play an important role in both processes. Monocytes are comprised of distinct subsets with different cell surface markers and functional characteristics and this heterogeneity may be relevant to angiogenic processes in atherosclerosis. The aim of the review article is to present an overview of the available evidence supporting a role for monocytes in angiogenesis and atherosclerosis.
Circulating myeloid cells can be recruited to sites of active angiogenesis and play a role in both maturation and stabilization of new vessels (Murdoch C, Muthana M, Coffelt S B, Lewis C E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008, 8(8): 618-631).
CD11b is a marker of macrophages, neutrophils, mast cells, and microglia. The CD11 protein is actually a heterodimer complex that consists of CD11b and CD18. CD11 is involved in numerous adhesion-related associations between cells such as monocytes, macrophages, natural killer (NK) cells, and granulocytes. CD11 also regulates the uptake of complement-coated particles within cells. It is also gained usage as a microglial marker for tissues derived from the nervous system.
In particular, a specific population of CD11b+ monocytes called Neuropilin-Expressing Monocytes (NEM), as they express Neuropilin-1 (Nrp1), a co-receptor for VEGF and Semaphorin 3A co-receptor, has been recently found to accelerate new vessel stabilization, both directly by activating TGF-b1 signaling (Groppa E, Brkic S, Bovo E, Reginato S, Sacchi V, Di Maggio N, et al. VEGF dose regulates vascular stabilization through Semaphorin3A and the Neuropilin-1+ monocyte/TGF-beta1 paracrine axis. EMBO Mol Med 2015, 7(10): 1366-1384) and indirectly by promoting pericyte recruitment through PDGF-BB secretion (Zacchigna S, Pattarini L, Zentilin L, Moimas S, Carrer A, Sinigaglia M, et al. Bone marrow cells recruited through the neuropilin-1 receptor promote arterial formation at the sites of adult neoangiogenesis in mice. J Clin Invest 2008, 118(6): 2062-2075).
Exosomes are cell-derived vesicles that are present in many eukaryotic fluids, and cultured medium of cell cultures. A sub-type of exosomes, defined as matrix-bound nanovesicles (MBVs), was reported to be present in extracellular matrix (ECM) bioscaffolds (non-fluid) (Huleihel L, et al. Matrix-bound nanovesicles within ECM bioscaffolds. Sci Adv. 2016 Jun. 10; 2(6):e1600502. doi: 10.1126/sciadv.1600502. eCollection 2016 Jun.). Exosomes have specialized functions and consequently there is a growing interest in the clinical applications of exosomes. Exosomes can potentially be used for therapy for disease.
In order to be therapeutically useful, newly induced vascular structures must stabilize, i.e. persist long-term without regression. Newly induced vessels require about 4 weeks to become independent of further angiogenic stimuli and persist indefinitely (Ozawa C R, Banfi A, Glazer N L, Thurston G, Springer M L, Kraft P E, et al. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest 2004, 113(4): 516-527). One of the challenges with local delivery of proangiogenic signals, such as VEGF, is that the sprouting and maturation of new vessels into normal or aberrant (tumor-like vessels) depends on the formation of precise concentration gradients in the vessel microenvironment. These depend both on the combination of different isoforms of VEGF with varying affinity for extracellular matrix and their local concentration, which are very difficult to modulate and control.
Liu et al. (in: Liu et al. Cutting Edge: Piezo1 Mechanosensors Optimize Human T Cell Activation. The Journal of Immunology Jan. 12, 2018, ji1701118) disclose that mechanical forces contribute to optimal T cell activation, as reflected by the superior efficiency of immobilized TCR-cross-linking Abs compared with soluble Abs in TCR triggering, although a dedicated mechanotransduction module is not known. They found that the mechanosensor protein Piezo1 is critically involved in human T cell activation, and provide the first evidence, to their knowledge, for the involvement of Piezo1 mechanosensors in immune regulation.
Ranade et al. (in: Ranade et al. Piezo1, a mechanically activated ion channel, is required for vascular development in mice. PNAS. 2014 Jul. 15; 111(28):10347-52) identified Piezo1 and Piezo1 as mechanically activated cation channels that Piezo1 is expressed in endothelial cells of developing blood vessels in mice and highlight an essential role of mammalian Piezo1 in vascular development during embryonic development.
Ma et al. (in: Common PIEZO1 Allele in African Populations Causes RBC Dehydration and Attenuates Plasmodium Infection. Cell. 2018; 173(2):443-455.e12. doi:10.1016/j.cell.2018.02.047) identify a human gain-of-function (GOF) PIEZO1 allele, E756del, present in a third of the African population which is associated with dehydrated RBCs and reduced Plasmodium infection in vitro. GOF Piezo1 was specifically expressed in macrophages, but the mice displayed survival rate and parasitemia curves similar to wild type littermates. These results indicate that macrophages are unlikely to play an essential role in reducing parasite growth rate and protection against experimental cerebral malaria in xerocytosis mice. The existence of a gain-of-function PIEZO1 at high frequencies and suggests an association with malaria resistance.
Li et al (in: Piezo1 integration of vascular architecture with physiological force. Nature. 2014 Nov. 13; 515(7526):279-282. doi: 10.1038/nature13701. Epub 2014 Aug. 10) identify the role of Piezo-1 in vascular architecture by showing that EC-specific disruption of mouse Piezo-1 profoundly disturbs vascular development. Piezo1 acts as sensor of shear stress in endothelial cells (ECs), and confers sensitivity to shear stress on otherwise resistant cells. Similarly, Sewduth and Santoro (in: “Decoding” Angiogenesis: New Facets Controlling Endothelial Cell Behavior. Front Physiol. 2016 Jul. 21; 7:306) disclose Piezo-1 as a determinant for vascular structure, and cilia and the expression of the channel protein PKD2 in mechanical forces-dependent angiogenesis.
In view of the above, there especially seems to be no prior art that describes the presence of a subpopulation of macrophage expressing CD11b and Piezo-1, and a role thereof in angiogenesis.
It would be highly beneficial to gain more insight into the factors that impact the organization of multiple ECs into freestanding tubular structures, in order to, for example, allow a better therapeutic use and control over angiogenic processes.
According to a first aspect of the present invention, this object is solved by an isolated mammalian CD11b+/PIEZO-1+ macrophage cell, neutrophil cell, and/or an isolated exosome as secreted by said cell.
In another aspect of the present invention, the object is solved by a pharmaceutical composition comprising the CD11b+/PIEZO-1+ macrophage cell, neutrophil cell, and/or the isolated exosome according to claim 1, together with a pharmaceutically acceptable carrier and/or auxiliary agent.
In yet another aspect of the present invention, the object is solved by a method for producing a pharmaceutical composition according to the present invention, comprising the steps of comprising the steps of a) providing a biological sample derived from a mammal comprising CD11b+ macrophages, neutrophil cells, or precursor monocytes thereof, b) in vitro differentiating said CD11b+ macrophages, neutrophil cells, or precursor monocytes into CD11b+ PIEZO-1+ macrophages or neutrophil cells, and c) formulating said purified and/or isolated CD11b+ PIEZO-1+ macrophages or neutrophil cells into a suitable pharmaceutical composition.
In yet another aspect of the present invention, the object is solved by a method for producing a pharmaceutical composition according to the present invention, comprising the steps of a) providing a biological sample derived from a mammal comprising CD11b+ macrophages, neutrophil cells or precursor monocytes thereof, b) in vitro differentiating said CD11b+ macrophages, neutrophil cells or precursor monocytes into CD11b+ PIEZO-1+ macrophages or neutrophil cells, and c) formulating said purified and/or isolated CD11b+ PIEZO-1+ macrophages or neutrophil cells into a suitable pharmaceutical composition.
In yet another aspect of the present invention, the object is solved by a method for diagnosing angiogenesis in a mammal, comprising identifying CD11b+ PIEZO-1+ macrophages, neutrophil cells, and/or exosomes as secreted by said cell in a sample from a mammal to be diagnosed, wherein the presence of CD11b+ PIEZO-1+ macrophages, neutrophil cells, and/or exosomes as secreted by said cell is indicative for angiogenesis in said mammal, when compared to a control sample.
In yet another aspect of the present invention, the object is solved by a method for identifying a compound that modulates the expression and/or the biological activity of PIEZO-1 in a CD11b+ macrophage or neutrophil cell, comprising the steps of a) contacting said CD11b+ macrophage or neutrophil cell with at least one compound that potentially modulates the expression and/or the biological activity of PIEZO-1 in said CD11b+ macrophage or neutrophil cell, and b) identifying a modulation of the expression and/or the biological activity of PIEZO-1 in the presence of said at least one compound, compared to a control CD11b+ macrophage or neutrophil cell.
In yet another aspect of the present invention, the object is solved by a method for manufacturing a pharmaceutical composition, comprising the steps of performing a method according to the present invention, and formulating said compound as identified into a pharmaceutical composition.
In yet another aspect of the present invention, the object is solved by an in vitro method for producing a CD11b+/PIEZO-1+ macrophage or neutrophil cell, comprising the steps of a) providing a biological sample, in particular blood, comprising CD11b+ macrophages, neutrophil cells or precursor monocytes, and b) in vitro differentiating said CD11b+ macrophages, neutrophil cells or precursor monocytes into CD11b+ PIEZO-1+ macrophages using suitable signal compounds, such as, for example, small molecules, cytokines, proteins, or peptides.
In yet another aspect of the present invention, the object is solved by a pharmaceutical composition according to the present invention or a pharmaceutical composition produced according to the present invention for use in treating insufficient angiogenesis in a mammalian patient.
In yet another aspect of the present invention, the object is solved by the use of a pharmaceutical composition produced according to the present invention for the in vitro production/induction of CD11b+ PIEZO-1+ macrophages and/or neutrophil cells.
In yet another aspect of the present invention, the object is solved by a screening tool for identifying a compound that modulates the expression and/or the biological activity of PIEZO-1 in a CD11b+ macrophage or neutrophil cell, comprising a recombinant CD11b+ macrophage or neutrophil cell comprising a genetic construct that allows for detecting the expression and/or the biological activity of PIEZO-1 in said CD11b+ macrophage or neutrophil cell, in particular an induction and/or increase of said expression and/or biological activity of PIEZO-1 in said macrophage or neutrophil cell.
In yet another aspect of the present invention, the object is solved by a kit comprising materials and reagents for performing a method according to the present invention.
In yet another aspect of the present invention, the object is solved by a method for treating or preventing an insufficient angiogenesis in a mammalian patient, comprising administering to said patient an effective amount of a pharmaceutical composition according to the present invention, or as produced according to the present invention.
Vascularization is a critical step in the restoration of cellular homeostasis. Several strategies including localized growth factor delivery, endothelial progenitor cells, genetically engineered cells, gene therapy, and pre-vascularized implants have been explored to promote re-vascularization. But, long-term stabilization of newly-induced vessels remains a challenge. It has been shown that fibroblasts and mesenchymal stem cells can stabilize newly-induced vessels. However, whether an injected biomaterial alone can serve as an instructive environment for angiogenesis remained to be elucidated.
The present invention is based on the surprising finding that appropriate vascular branching, and long-term stabilization can be promoted simply by implanting a hydrogel with stiffness matching that of fibrin clot. During experiments in the context of the present invention in order to identify an underlying physiological mechanism, the inventors surprisingly identified a new and unique sub-population of circulating CD11b+ myeloid cells that express the stretch activated cation channel Piezo-1 which is recruited in the muscle-like hydrogel and in the fibrin clot-like hydrogel. These findings offered also evidence for a mechanobiology paradigm in angiogenesis involving an interplay between mechano-sensitive circulating cells and mechanics of tissue microenvironment.
The present invention thus employs the above findings in the context of conditions related to angiogenesis in several ways.
First, a yet unknown method for diagnosing angiogenesis in a mammal can be established, where CD11b+ PIEZO-1+ macrophages, neutrophil cells, and/or exosomes as secreted by said cell in a sample from a mammal to be diagnosed are suitably identified. The presence of these CD11b+ PIEZO-1+ macrophages, neutrophil cells and/or exosomes as secreted by said cell is then indicative for angiogenesis in said mammal, when compared to a control sample. Said identifying can further comprise detecting the amount of said CD11b+ PIEZO-1+ macrophages, neutrophil cells and/or the level of expression and/or the levels of the biological activity of CD11b+ and PIEZO-1+ in said macrophages and/or neutrophil cells in said sample. Consequently, an increase of the amount of said CD11b+ PIEZO-1+ macrophages and/or neutrophil cells and/or the level of expression and/or the levels of the biological activity of CD11b+ and PIEZO-1+ in said macrophages and/or neutrophil cells, when compared to a control, is indicative for an increased angiogenesis.
Methods to detect the amount of said CD11b+ PIEZO-1+ macrophages and/or neutrophil cells and/or the level of expression and/or the levels of the biological activity of CD11b+ and PIEZO-1+ in said macrophages and/or neutrophil cells in said sample are known to the person of skill, and may comprises the use of beads, such as Dynal® beads or cell sorting, such as fluorescence activated cell sorting (FACS®). Furthermore, methods based on marker specific antibodies (CD11b+ and/or PIEZO-1+), or respective quantitative PCR, such as rtPCR, are known, and can be used.
Second, since the mammalian CD11b+/PIEZO-1+ macrophage cell, neutrophil cell and/or an isolated exosome as secreted by said cell according to the present invention are relevant for angiogenesis, the cells and/or the exosomes themselves provide valuable pharmaceutical compounds and components. Hence, the present invention provides such components, preferably as a pharmaceutical composition comprising the CD11b+/PIEZO-1+ macrophage cell, neutrophil cell and/or the isolated exosome according to the present invention, together with a pharmaceutically acceptable carrier and/or auxiliary agent.
In particularly preferred embodiments of the pharmaceutical composition according to the present invention said pharmaceutical composition further advantageously comprises a matrix material selected from the group of alginate, hyaluronic acid, agarose, poloxamers (e.g. Pluronic®), polyethylene (PEG) hydrogels, and a modified primary hydroxyl groups containing polysaccharide comprising repeating disaccharide units, such as, for example, agarose, wherein in at least part of the disaccharide units the primary hydroxyl group is replaced by functional groups selected from halide groups or groups comprising sulfur or phosphorus atoms, such as, for example, sulfate groups, sulfonate groups, phosphonate groups and phosphate groups, preferably carboxylated agarose and phosphate agarose. This biomaterial can serve as an (additional) instructive environment for angiogenesis.
Generally, such a pharmaceutical composition according the present invention can be produced following the steps of a) providing a biological sample derived from a mammal comprising CD11b+ macrophage cells, neutrophil cells and/or exosomes as secreted by said cells, b) purifying and/or isolating CD11b+ PIEZO-1+ macrophage cells and/or neutrophil cells from said sample based on the expression of CD11b+ and PIEZO-1+, and/or purifying and/or isolating exosomes as secreted by said cell based on their content of CD11b+ and PIEZO-1+, and
Nevertheless, the present invention also relates to several other useful pharmaceutical compositions and related methods of making these. In one aspect, these pharmaceutical compositions comprise a compound that modulates the expression and/or the biological activity of PIEZO-1 in a CD11b+ macrophage or neutrophil cell (or precursors thereof). Preferably, said modulation is an induction and/or increase of said expression and/or biological activity of PIEZO-1 in said macrophage or neutrophil cell (or precursors thereof).
This compound can be used in an in vitro method for producing a CD11b+/PIEZO-1+ macrophage or neutrophil cell, comprising the steps of a) providing a biological sample, in particular blood, comprising CD11b+ macrophages, neutrophil cells, or precursor monocytes, and b) in vitro differentiating said CD11b+ macrophages, neutrophil cells, or precursor monocytes into CD11b+ PIEZO-1+ macrophages or neutrophil cells using suitable signal compounds, such as, for example, small molecules, cytokines, proteins, or peptides. Since CD11b+/PIEZO-1+ macrophages or neutrophil cells present a new group of yet unknown cells, not all compounds are known, and an inventive method for identifying a compound that modulates the expression and/or the biological activity of PIEZO-1 in a CD11b+ macrophage or neutrophil cell can be used that comprises the steps of a) contacting said CD11b+ macrophage or neutrophil cell with at least one compound that potentially modulates the expression and/or the biological activity of PIEZO-1 in said CD11b+ macrophage or neutrophil cell, and b) identifying a modulation of the expression and/or the biological activity of PIEZO-1 in the presence of said at least one compound, compared to a control CD11b+ macrophage. Preferably said compound is selected from the group consisting of a peptide library, a combinatory library, a cell extract, in particular a plant cell extract, a “small molecular drug”, an antisense oligonucleotide, an siRNA, and an mRNA. Performing such screening methods is well-known in the art, for example a “contacting” in the present invention means any interaction between the potentially binding substance(s) with the CD11b+ macrophage or a precursor cell, whereby any of the two components can be independently of each other in a liquid phase, for example in solution, or in suspension or can be bound to a solid phase, for example, in the form of an essentially planar surface or in the form of part isles, pearls or the like. In a preferred embodiment a multitude of different potentially binding substances are immobilized on a solid surface like, for example, on a compound library chip and the CD11b+ macrophage or neutrophil cell or a precursor cell thereof is subsequently contacted with such a chip.
Measuring of binding of the compound to the CD11b+ macrophage, neutrophil cell or a precursor cell can be carried out either by measuring a marker that can be attached either to the cell (or is a marker for said cell) or to the potentially interacting compound. Suitable markers are known to someone of skill in the art and comprise, for example, fluorescence or radioactive markers. As a further step after measuring the binding of a potentially interacting compound and after having measured at least two different potentially interacting compounds at least one compound can be selected, for example, on grounds of the measured binding activity or on grounds of the detected increase or decrease of binding activity and/or expression.
The thus selected binding compound is then in a preferred embodiment modified in a further step. Modification can be effected by a variety of methods known in the art, which include without limitation the introduction of novel side chains or the exchange of functional groups like, for example, introduction of halogens, in particular F, Cl or Br, the introduction of lower alkyl groups, preferably having one to five carbon atoms like, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or iso-pentyl groups, lower alkenyl groups, preferably having two to five carbon atoms, lower alkynyl groups, preferably having two to five carbon atoms or through the introduction of, for example, a group selected from the group consisting of NH2, NO2, OH, SH, NH, CN, aryl, heteroaryl, COH or COOH group.
In another aspect, the pharmaceutical compositions are produced by a method comprising in vitro differentiating of said CD11b+ macrophages, neutrophil cells, or precursor monocytes into CD11b+ PIEZO-1+ macrophages or neutrophil cells, comprising the steps of a) providing a biological sample derived from a mammal comprising CD11b+ macrophages, neutrophil cells or precursor monocytes thereof, b) in vitro differentiating said CD11b+ macrophages, neutrophil cells or precursor monocytes into CD11b+ PIEZO-1+ macrophages or neutrophil cells, and c) formulating said purified and/or isolated CD11b+ PIEZO-1+ macrophages or neutrophil cells into a suitable pharmaceutical composition. Preferably, said purifying and/or isolating comprises the use of beads, such as Dynal® beads or cell sorting, such as fluorescence activated cell sorting (FACS®), e.g. based on suitable cellular markers as described herein.
In another aspect, the method according to the present invention further comprises a suitable in vitro expansion of the CD11b+ PIEZO-1+ macrophages or neutrophil cells before formulating into a pharmaceutical composition.
In general, disclosed is a method according to the present invention for manufacturing a pharmaceutical composition, comprising the steps of performing a method according to the present invention as above, and formulating said compound as identified into a pharmaceutical composition. The pharmaceutical compositions of the invention are preferably sterile and contain an effective amount of the agents described herein and optionally of further agents as discussed herein to generate the desired reaction or the desired effect, e.g. a pharmaceutical angiogenetic effect or a differentiation of said CD11b+ macrophages or neutrophil cells or precursor monocytes into CD11.13+ PIEZO-1+ macrophages or neutrophil cells. Pharmaceutical compositions are usually provided in a uniform dosage form and may be prepared in a manner known per se. A pharmaceutical composition may e.g. be in the form of a solution or suspension. A pharmaceutical composition may comprise salts, buffer substances, preservatives, carriers, diluents and/or excipients all of which are preferably pharmaceutically acceptable. The term “pharmaceutically acceptable” refers to the non-toxicity of a material which does not interact with the action of the active component of the pharmaceutical composition. Saks which are not pharmaceutically acceptable may be used for preparing pharmaceutically acceptable salts and are included in the invention. Pharmaceutically acceptable salts of this kind comprise in a non-limiting way those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, salicylic, citric, formic, malonic, succinic acids, and the like. Pharmaceutically acceptable salts may also be prepared as alkali metal salts or alkaline earth metal salts, such as sodium salts, potassium salts or calcium salts.
Suitable buffer substances for use in a pharmaceutical composition include acetic acid in a salt, citric acid in a salt, boric acid in a salt and phosphoric acid in a salt. Suitable preservatives for use in a pharmaceutical composition include benzalkonium chloride, chlorobutanol, paraben and thimerosal. An injectable formulation may comprise a pharmaceutically acceptable excipient such as Ringer Lactate.
The term “carrier” refers to an organic or inorganic component, of a natural or synthetic nature, in which the active component is combined in order to facilitate, enhance or enable application. According to the invention, the term “carrier” also includes one or more compatible solid or liquid fillers, diluents or encapsulating substances, which are suitable for administration to a patient. Possible carrier substances for parenteral administration are e.g. sterile water. Ringer, Ringer lactate, sterile sodium chloride solution, polyalkylene glycols, hydrogenated naphthalenes and, in particular, biocompatible lactide polymers, lactide/glycolide copolymers or polyoxyethylene/polyoxy-propylene copolymers. The term “excipient” when used herein is intended to indicate all substances which may be present in a pharmaceutical composition and which are not active ingredients such as, e.g., carriers, binders, lubricants, thickeners, surface active agents, preservatives, emulsifiers, buffers, flavoring agents, or colorants. The agents and compositions described herein may be administered via any conventional route, such as by parenteral administration including by injection or infusion. Administration is preferably parenterally, e.g. intravenously, intra-arterially, subcutaneously, intra-dermally or intramuscularly. Compositions suitable for parenteral administration usually comprise a sterile aqueous or non-aqueous preparation of the active compound, which is preferably isotonic to the blood of the recipient. Examples of compatible carriers and solvents are Ringer solution and isotonic sodium chloride solution. In addition, usually sterile, fixed oils are used as solution or suspension medium.
The agents and compositions described herein are administered in effective amounts. An “effective amount” refers to the amount which achieves a desired reaction or a desired effect alone or together with further doses. In the case of treatment of a particular disease or of a particular condition, the desired reaction preferably relates to inhibition of the course of the disease. This comprises slowing down the progress of the disease and, in particular, interrupting or reversing the progress of the disease, in the present context by influencing angiogenesis. The desired reaction in a treatment of a disease or of a condition may also be delay of the onset or a prevention of the onset of said disease or said condition.
An effective amount of an agent or composition described herein will depend on the condition to be treated, the severity of the disease, the individual parameters of the patient, including age, physiological condition, size and weight, the duration of treatment, the type of an accompanying therapy (if present), the specific route of administration and similar factors. Accordingly, the doses administered of the agents described herein may depend on several of such parameters. In the case that a reaction in a patient is insufficient with an initial dose, higher doses (or effectively higher doses achieved by a different, more localized route of administration) may be used. The agents and compositions described herein can be administered to patients, e.g., in vivo, to treat or prevent a variety of disorders such as those described herein. Preferred patients include human patients having disorders that can be corrected or ameliorated by administering the agents and compositions described herein having a desired effect on angiogenesis.
Preferably, said pharmaceutical composition according to the present invention can be used for the in vitro production/induction of CD11b+ PIEZO-1+ macrophages or neutrophil cells as described herein.
Further preferably, said pharmaceutical composition according to the present invention is for administration to a patient in need thereof, and wherein said CD11b+ macrophages, neutrophil cells or precursor monocytes thereof are autologous, heterologous, such as xenogeneic, to said patient.
Even further preferably, said pharmaceutical composition according to the present invention or the pharmaceutical composition produced according to the present invention is for use in treating insufficient angiogenesis in a mammalian patient, as also described above. Consequently, another aspect of the present invention then relates to method for treating or preventing an insufficient angiogenesis in a mammalian patient, comprising administering to said patient an effective amount of a pharmaceutical composition according to the invention as above. In general, the attending physician will base a treatment on the compound as identified, and optionally also on other individual patient data (clinical data, family history, DNA, etc.), and a treatment can also be performed based on the combination of these factors. This method of the present invention for example involves integrating individual diagnostic disease data with patient clinical information and general healthcare statistics to enable, for example, the application of personalized medicine to the patient. Significant information about drug effectiveness, drug interactions, and other patient status conditions can be used, too. Preferred is a therapeutic method according to the present invention, wherein said mammal to be treated is a mouse, rat or human.
According to yet another aspect thereof, the object of the present invention is solved by providing a method for treating or preventing an insufficient angiogenesis in a mammalian patient, comprising administering to said patient an effective amount of a pharmaceutical composition according to the present invention or as produced according to the present invention. As mentioned above, an effective amount of an agent or composition described herein will depend on the condition to be treated, the severity of the disease, the individual parameters of the patient, including age, physiological condition, size and weight, the duration of treatment, the type of an accompanying therapy (if present), the specific route of administration and similar factors. Accordingly, the doses administered of the agents described herein may depend on several of such parameters. In the case that a reaction in a patient is insufficient with an initial dose, higher doses (or effectively higher doses achieved by a different, more localized route of administration) may be used.
According to yet another aspect thereof, the object of the present invention is solved by providing a screening tool for identifying a compound that modulates the expression and/or the biological activity of PIEZO-1 in a CD11b+ macrophage or neutrophil cell, comprising a recombinant CD11b+ macrophage or neutrophil cell or a precursor cell thereof comprising a genetic construct that allows for detecting the expression and/or the biological activity of PIEZO-1 in said CD11b+ macrophage or neutrophil cell, in particular an induction and/or increase of said expression and/or biological activity of PIEZO-1 in said macrophage or neutrophil cell or a precursor cell thereof. Said CD11b+ macrophages, neutrophil cells or precursor cells (monocytes) thereof can be autologous, heterologous, such as xenogeneic, to said patient.
According to yet another aspect thereof, the object of the present invention is solved by providing a kit comprising materials and reagents for performing a method according to the present invention. The kit according to the invention may also incorporate various media or devices for performing the method according to the invention. Said kit can also be included in an automatic device such as a high throughput screening apparatus for the detection and/or the quantification of a sample to be analyzed. Said kit or apparatus can be adapted for performing all the steps or only several specific steps of the methods according to the invention. In one embodiment, the kit further comprises instructions for use of the kit in a method according to the invention.
During angiogenesis, ECs express the αv family of integrins, which are transmembrane proteins that specifically bind to the arginine-glycine-aspartic acid (RGD) sequence found in many ECM molecules, including collagen, fibronectin, and vitronectin (9) Since integrins are also anchored to the actin cytoskeleton of the cell (10), they function as mechanotransducers and assist the cells in perceiving the mechanics of the ECM; and it has been shown that integrin signaling is necessary for both EC survival and proliferation. In spite of this compelling evidence linking mechanical cues to EC function and, the impact of the ECM mechanical properties on blood vessel sprouting and maturation remains unknown. The inventors had recently demonstrated in vitro that ECs when presented with a hydrogel environment of defined stiffness in combination with RGD-signaling and soluble pro-angiogenic signals can undergo apical-basal polarization and organize into free standing multicellular lumens even in absence of mural support cells. Encouraged by this observation in this study the inventors inquired if the mere introduction of such biomaterials with defined mechanical properties could be sufficient to promote maturation and stabilization of neovasculature. Specifically, the inventors chose a 2 wt-% solution of carboxylated agarose (CA) of 28% and 60% carboxylation as they yielded injectable gels representing two distinct stiffness (shear moduli) spanning one order of magnitude (5 kPa and 0.5 kPa, respectively) that mimic the mechanical properties of muscle (1.5-3.5 kPa) (13), and fibrin network on blot clot (0.06-0.6 kPa) (14), respectively; and additionally, can be formed in situ at physiological acceptable temperatures. To ensure mechanical coupling of ECs with the gel and to exploit the known benefits of RGD signaling maintenance of EC function, the CA was functionalized with peptide presenting the GGGGRGDSP sequence in the N-terminus using aqueous 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) chemistry. Since RGD ligand density is known to impact cell-biomaterial interaction the reaction conditions were optimized to ensure an optimal density.
CA hydrogels of 5 kPa and 0.5 kPa stiffness, with or without soluble growth factor supplementation (GF) (four conditions), were implanted into gastrocnemius muscles, a target tissue relevant for periphery artery diseases, of SCID mice in order to evaluate the potential angiogenic response. Hematoxylin and Eosin staining showed that after 2 weeks, hydrogels were clearly evident in all conditions and well tolerated by the muscle tissue (
Since CA have a unique property profile such as tunable mechanical properties and in situ gelation (12), the observed tissue compatibility bodes well for the further utilization of CA in investigating mechanobiology paradigms. The ability of the CA gels to stimulate the ingrowth of blood micro-vessels into its avascular environment was investigated by immunofluorescence and confocal microscopy. All compositions were efficiently invaded by newly formed micro-vessels, physiologically associated with mural cells, i.e. pericytes (positive for nerve/glial antigen 2 (NG2) and negative for a-SMA), and smooth muscle cells (positive for a-SMA) (
Matrigel—a matrix derived from Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells rich in basal lamina proteins and growth factors (16)—has been shown to be highly supportive of vascular growth, and is therefore widely used to stimulate angiogenesis both in vitro and in vivo. In order to further improve the supportive properties of the hydrogel for vascular ingrowth, the different compositions were supplemented with Matrigel (0.01% w/v) and the outcomes were ascertained after two weeks implantation in muscle.
It is important to note that the addition of Matrigel has no impact on the mechanical properties of the gel as shown earlier. All hydrogels were well integrated in the muscle tissue, similar to the unsupplemented conditions. The amount of micro-vascular ingrowth induced by the addition of Matrigel was similar to stiffness environments with GF (5 kPa+ Mat=4.4±0.4 and 0.5 kPa+ Mat=4.8±0.3 mm/mm2) although slightly increased compared to vascular density induced by hydrogels alone (p=n.s. vs 5 kPa and 0.5 kPa). However, Matrigel addition caused capillary networks that were much less branched, as evidenced by the significantly longer average segment length (5 kPa+ Mat=671.4±118.5 μm, vs 5 kPa=277.1±41.5; 0.5 kPa+ Mat=1115.0±140.3 μm, vs 0.5 kPa=207.8±48.2 μm and p<0.0001), suggesting a less beneficial connectivity compared to both hydrogel conditions. Furthermore, in the presence of Matrigel, vascular morphology was still that of normal capillaries but with a moderately smaller caliber compared to the unsupplemented hydrogel alone conditions (5 kPa+ Mat=6.4±0.2 μm vs 5 kPa=7.7±0.2 μm, **** p<0.0001 and 0.5 kPa+ Mat=6.0±0.2 vs 0.5 kPa=8.2±0.2 μm, **** p<0.0001). Overall, these data show that Matrigel supplementation did not improve the early pro-angiogenic properties of the hydrogels alone.
In order to be therapeutically useful, newly induced vascular structures must stabilize, i.e. persist long-term without regression. Newly induced vessels require about 4 weeks to become independent of further angiogenic stimuli and persist indefinitely (19). Therefore, the fate of initially induced vascular structures was investigated 7 weeks after implantation of 5 and 0.5 kPa hydrogels with and without GF in murine hind limb muscles. Since GF and Matrigel supplementation yielded similar outcomes, the condition with GF alone was included in this experiment in order to account for their role during initial vessel induction. Masson trichrome staining revealed that compared to the 2-week 125 time point, after 7 weeks hydrogels continue to persist at the site of implantation, supported efficient infiltration of host cells, and induced no foreign-body reaction as assessed by the absence of a collagenous capsule, suggesting that the gels were integrated in muscle tissue. Quantification of the vasculature showed a significant regression of the capillaries initially induced within the 5 kPa hydrogels, as VLD was reduced by >50% compared to the 2-week time-point from 4.4±0.4 to 1.7±0.2 mm/mm2 (p<0.0001), although GF supplementation allowed a better stabilization (VLD 7 wk=5.0±0.8 mm/mm2 vs 2 wk=4.7±0.3 mm/mm2, p=n.s.) (
Therefore, the establishment of functional blood flow in newly induced vascular structures was assessed by intravenous injection of biotinylated tomato lectin 150 that binds the luminal surface of blood vessels and marks only vessels that are functionally perfused by the systemic circulation. Quantification of lectin perfusion showed that vessels in all conditions were well perfused (about 70% of lectin+ endothelial structures), with only the 5 kPa gels showing a moderate reduction to about 50% (
Since the 0.5 kPa gels at 7 weeks showed a moderate increase in the amount of newly induced capillaries compared to 2-week time-point, endothelial proliferation was investigated by immunostaining for Ki67, which marks the nucleus of cells in all phases of the cell cycle (G1, S, G2, and M), excluding quiescent ones (Go) (22). Quantification of Ki67+ endothelial nuclei showed that vascular networks in all gel compositions were essentially quiescent, with at least 98% of ECs in Go phase (
Circulating myeloid cells can be recruited to sites of active angiogenesis and play a role in both maturation and stabilization of new vessels (24). In particular, a specific population of CD11b+ monocytes called Neuropilin-Expressing Monocytes (NEM), as they express Neuropilin-1 (Nrp1), a co-receptor for VEGF and Semaphorin3A co-receptor, has been recently found to accelerate new vessel stabilization, both directly by activating TGF-b1signaling and indirectly by promoting pericyte recruitment through PDGF-BB secretion.
Therefore, the inventors investigated whether the long-term stabilization of the capillary networks by the 0.5 kPa hydrogel could relate to a differential recruitment of myeloid cells and specifically pro-maturative CD11b+ monocytes. Two weeks after implantation into hind limb muscles, immunofluorescent staining showed that the 0.5 kPa hydrogels recruited about 40% more CD45+ myeloid cells than the harder 5 kPa composition (476.9±37.7 vs 333.8±44.7 cells/field, p<0.01;
Since mechanical stiffness was the only difference between the hydrogel promoting vessel stabilization and persistence (softer, 0.5 kPa) and the ineffective one (harder, 5 kPa), the inventors inquired if there exists a mechano-sensitive cell population that is preferentially recruited to the softer hydrogel microenvironment. Immunofluorescence staining identified for the first time a hitherto unknown population of CD11b+ monocytes expressing Piezo-1 (
Interestingly, the frequency of this population of mechano-sensitive monocytes was similar in mouse and human circulation, accounting for 35.0±2.2% and 35.1±9.1% of total CD11b+ monocytes respectively (p=n.s.;
The role of immune cells in regenerative medicine is an emerging theme. It has been recently shown that T helper 2 (Th2) lymphocytes, which comprise adaptive immunity play an important role in facilitating muscle tissue regeneration by ECM-based biomaterials. Interestingly, the inventors' data show that the purely angiogenic effect of vessel stabilization by a mechanically defined environment does not require adaptive immunity, as this is lacking in the SCID mice. It is worth noting that in pulmonary inflammation recruitment of CD11b+ myeloid cells have been found to be critical in the homing of activated Th2 lymphocytes and orchestration of an adaptive immune response. Since the introduction of the gel in the muscle environment is bound to invoke an inflammatory response, the presence of CD11b+ cells could be a consequence of an inflammatory response. Considering these observations and the recently identified functions of CD11b+ monocytes in regulating the stabilization of newly induced vessels, the novel population of CD11b+/CD115+/Piezo1+ monocytes identified here may represent the link between the mechanics and angiogenic properties of hydrogels and represents a novel direction for future efforts in developing systems and pharmacological agents for therapeutic angiogenesis.
Vascularization is a critical step in the restoration of cellular homeostasis. Several strategies including localized growth factor delivery, endothelial progenitor cells, genetically engineered cells, gene therapy, and pre-vascularized implants have been explored to promote re-vascularization. But, long-term stabilization of newly-induced vessels remains a challenge. It has been shown that fibroblasts and mesenchymal stem cells can stabilize newly-induced vessels. However, whether an injected biomaterial alone can serve as an instructive environment for angiogenesis remains to be elucidated. The inventors found that appropriate vascular branching, and long-term stabilization can be promoted simply by implanting a hydrogel with stiffness matching that of fibrin clot. They have furthermore identified a unique sub-population of circulating CD11b+ myeloid cells that express the stretch activated cation channel Piezo-1 which is enriched prominently in the clot-like hydrogel. These findings offer evidence for a mechanobiology paradigm in angiogenesis involving an interplay between mechano-sensitive circulating cells and mechanics of tissue microenvironment.
Therefore, the present invention relates to the following items.
An isolated mammalian CD11b+/PIEZO-1+ macrophage cell, neutrophil cell, and/or an isolated exosome as secreted by said cell.
A pharmaceutical composition comprising the CD11b+/PIEZO-1+ macrophage cell, neutrophil cell, and/or the isolated exosome according to Item 1, together with a pharmaceutically acceptable carrier and/or auxiliary agent.
The pharmaceutical composition according to Item 2, further comprising a matrix material selected from the group of alginate, hyaluronic acid, agarose, poloxamers (e.g. Pluronic®), polyethylene (PEG) hydrogels, and a modified primary hydroxyl groups containing polysaccharide comprising repeating disaccharide units, such as, for example, agarose, wherein in at least part of the disaccharide units the primary hydroxyl group is replaced by functional groups selected from halide groups or groups comprising sulfur or phosphorus atoms, such as, for example, sulfate groups, sulfonate groups, phosphonate groups and phosphate groups, preferably carboxylated agarose and phosphate agarose.
A method for producing a pharmaceutical composition according to Item 2 or 3, comprising the steps of a) providing a biological sample derived from a mammal comprising CD11b+ macrophages and/or exosomes as secreted by said cells, b) purifying and/or isolating CD11b+ PIEZO-1+ macrophages or neutrophil cells from said sample based on the expression of CD11b+ and PIEZO-1+, and/or purifying and/or isolating exosomes as secreted by said cell based on their content of CD11b+ and PIEZO-1+, and c) formulating said purified and/or isolated CD11b+ PIEZO-1+ macrophages and/or exosomes into a suitable pharmaceutical composition.
The method according to Item 4, wherein said purifying and/or isolating comprises the use of beads, such as Dynal® beads or cell sorting, such as fluorescence activated cell sorting (FACS®).
A method for producing a pharmaceutical composition according to Item 2 or 3, comprising the steps of a) providing a biological sample derived from a mammal comprising CD11b+ macrophages or precursor monocytes thereof, b) in vitro differentiating said CD11b+ macrophages, neutrophil cells, or precursor monocytes into CD11b+ PIEZO-1+ macrophages or neutrophil cells, and c) formulating said purified and/or isolated CD11b+ PIEZO-1+ macrophages or neutrophil cells into a suitable pharmaceutical composition.
The method according to Item 6, wherein said pharmaceutical composition is for administration to a patient in need thereof, and wherein said CD11b+ macrophages, neutrophil cells, or precursor monocytes thereof are autologous, heterologous, such as xenogeneic, to said patient.
The method according to any one of Items 4 to 7, further comprising a suitable in vitro expansion of the CD11b+ PIEZO-1+ macrophages or neutrophil cells before formulating into said pharmaceutical composition.
A method for diagnosing angiogenesis in a mammal, comprising identifying CD11b+ PIEZO-1+ macrophages, neutrophil cells and/or exosomes as secreted by said cell in a sample from a mammal to be diagnosed, wherein the presence of CD11b+ PIEZO-1+ macrophages, neutrophil cells and/or exosomes as secreted by said cell is indicative for angiogenesis in said mammal, when compared to a control sample.
A method for diagnosing inflammation in a mammal, comprising identifying CD11b+ PIEZO-1+ macrophages, neutrophil cells and/or exosomes as secreted by said cell in a sample from a mammal to be diagnosed, wherein the presence of CD11b+ PIEZO-1+ macrophages, neutrophil cells and/or exosomes as secreted by said cell is indicative for inflammation in said mammal, when compared to a control sample.
The method according to Item 9 or 9a, wherein said identifying further comprises detecting the amount of said CD11b+ PIEZO-1+ macrophages and/or neutrophil cells and/or the level of expression and/or the levels of the biological activity of CD11b+ and PIEZO-1+ in said macrophages and/or neutrophil cells in said sample, wherein an increase of the amount of said CD11b+ PIEZO-1+ macrophages and/or neutrophil cells and/or the level of expression and/or the levels of the biological activity of CD11b+ and PIEZO-1+ in said macrophages and/or neutrophil cells, when compared to a control, is indicative for an increased angiogenesis or inflammation.
A method for identifying a compound that modulates the expression and/or the biological activity of PIEZO-1 in a CD11b+ macrophage and/or neutrophil cell, comprising the steps of a) contacting said CD11b+ macrophage and/or neutrophil cell with at least one compound that potentially modulates the expression and/or the biological activity of PIEZO-1 in said CD11b+ macrophage and/or neutrophil cell, and b) identifying a modulation of the expression and/or the biological activity of PIEZO-1 in the presence of said at least one compound, compared to a control CD11b+ macrophage.
The method according to Item to, wherein said modulation is an induction and/or increase of said expression and/or biological activity of PIEZO-1 in said macrophage and/or neutrophil cell.
The method according to Item 11 or 12, wherein said compound is selected from the group consisting of a peptide library, a combinatory library, a cell extract, in particular a plant cell extract, a “small molecular drug”, an antisense oligonucleotide, an siRNA, and an mRNA.
A method for manufacturing a pharmaceutical composition, comprising the steps of performing a method according to any one of Items 11 to 13, and formulating said compound as identified into a pharmaceutical composition.
An in vitro method for producing a CD11b+/PIEZO-1+ macrophage and/or neutrophil cell, comprising the steps of a) providing a biological sample, in particular blood, comprising CD11b+ macrophages or precursor monocytes, and b) in vitro differentiating said CD11b+ macrophages or precursor monocytes into CD11b+ PIEZO-1+ macrophages and/or neutrophil cells using suitable signal compounds, such as, for example, small molecules, cytokines, proteins, or peptides.
A pharmaceutical composition according to Item 2 or 3 or a pharmaceutical composition produced according to Item 14 for use in treating insufficient angiogenesis in a mammalian patient.
Use of a pharmaceutical composition produced according to Item 14 for the in vitro production/induction of CD11b+ PIEZO-1+ macrophages and/or neutrophil cells.
A screening tool for identifying a compound that modulates the expression and/or the biological activity of PIEZO-1 in a CD11b+ macrophage, comprising a recombinant CD11b+ macrophage and/or neutrophil cell comprising a genetic construct that allows for detecting the expression and/or the biological activity of PIEZO-1 in said CD11b+ macrophage and/or neutrophil cell, in particular an induction and/or increase of said expression and/or biological activity of PIEZO-1 in said macrophage and/or neutrophil cell.
A kit comprising materials and reagents for performing a method according to any one of Items 9 to 13.
A method for treating or preventing an insufficient angiogenesis in a mammalian patient, comprising administering to said patient an effective amount of a pharmaceutical composition according to any one of Items 2, 3, or as produced according to Item 14.
The present invention is described in detail by the figures and examples below, which are used only for illustration purposes and are not meant to be limiting. Owing to the description and the examples, further embodiments which are likewise included in the invention are accessible to the skilled worker.
Native agarose (1 g) (Merck, Darmstadt, Germany) was transferred into a 3-necked round bottom flask equipped with a mechanical stirrer and pH-meter (WTW, Weilheim, Germany), and dissolved in deionized water at a concentration of 1% w/v by heating to 90° C. The flask was cooled down to 0° C., using an ice bath, under vigorous mechanical stirring in order to prevent gelation of the agarose, and the reactor was charged with 99% (2,2,6,6-tetramethylpiperidin-1-yl)oxyl (TEMPO) (20.6 mg, 0.16 mmol), NaBr (0.1 g, 0.9 mmol), and NaOCl (2.5 mL, 15% solution) all obtained from Sigma Aldrich (Steinheim, Germany). As the reaction occurs, the solution becomes acidic. The pH of the solution was maintained at 10.8 by dropwise addition of NaOH (0.1 M) (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) throughout the duration of the reaction. The degree of carboxylation was back calculated by using the volumes of NaOH (0.1 M) solution added during the reaction. The reaction was quenched by the addition of NaBH4 (0.1 g) (Sigma-Aldrich Chemie GmbH, Steinheim, Germany), following which the solution was acidified to pH 8 (0.1 mHCl) and stirred for 1 h. The modified agarose was then precipitated by the sequential addition of NaCl (12 g, 0.2 mol) and ethanol (500 mL) (technical grade). The product was collected by vacuum filtration using a fritted glass funnel and then washed using ethanol (500 mL). The ethanol, catalyst, and salts were removed by extensive dialysis against water for 2 days with replacement of the water every 12 h. The modified agarose was then freeze-dried on a Beta 2-8 LD (Martin Christ Gefriertrocknungsanlagen GmbH, Osterode am Harz, Germany) overnight to yield a white solid. The degree of carboxylation was verified by the appearance of peaks associated with aliphatic carboxylic acid groups via FTIR (KBr) (vc=0: 1750 cm-1) (Bruker Optics, Ettlingen, Germany) and NMR300 Mhz (13C: 180 ppm) (Bruker BioSpin, Rheinstetten, Germany).
Rheology experiments were performed with a Physica MCR 301 (Anton Paar, Wundschuh, Austria) equipped with a Peltier cell to control the temperature and the experiment was performed with a plate geometry PPR25 (Anton Paar, 250 Wundschuh, Austria). Samples in deionized water were prepared by heating at 90° C. for 10 min until a clear solution was obtained. The liquid was then poured on the rheometer plate and the following sequence was used to determine the shear modulus: cool down from 80° C. to 5° C. in 30 min, 30 min equilibration at 5° C. to allow the gel to form, followed by heating to 37° C. and equilibration for 30 min prior to measuring G′ and G″ by increasing the rotation frequency from 0.01 rad/s up to 10 rad/s with a 1% deformation. The G′ of the gel was determined at 1 Hz shear frequency.
Functionalization of CA with the RGDSP (Peptides International, Louisville, Ky., USA) peptide was performed using 1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide (EDC) (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) coupling chemistry. CA was sterilized overnight in 70% ethanol, and the ethanol was re-moved by extensive dialysis against water.
The sterile CA was freeze-dried overnight to yield a white solid. CA (30 mg, 0.25 μmol) was dissolved in MES sterile buffer (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) and an excess EDC (210 mg, 1.3 mmol) was added and the solution stirred for 30 min. Following this the peptide was added (500 μg, 0.66 μmol for the CA-60 gels and 1 mg, 1.33 μmol for the gels) and the solution stirred for an additional 2 h at room temperature. Unreacted reagents were removed by dialysis against water. RGD incorporation was verified using elemental analysis Vario EL (Elementar Analysen systeme GmbH, Langenselbold, Germany) equipped with a thermal conductivity detector and an adsorption column for CO2 at 110° C. and H2O at 150° C. All samples were accurately weighed to 3 mg before measurements and the percentage of nitrogen was used to calculate the peptide attachment. It was found that 11.6±0.9% of the repeat units where functionalized on both CA-28 and CA-60.
Gels were implanted into 10-15 week old immune-deficient SCID CB.17 mice (Charles River Laboratories, Sulzfeld, Germany). Animals were treated in accordance with Swiss Federal guidelines for animal welfare, and the study protocol was approved by the Veterinary Office of the Canton of Basel-Stadt (Basel, Switzerland; Permit 2071). Gels were pre-loaded in 1 ml syringes and kept on ice. Fifty μl of cold PBS (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) followed by 50 μ1 of cold gels were implanted in both the medialis and lateralis portions of Gastrocnemius (GC) leg muscle, using a syringe with a 291/2G needle (Becton Dickinson, Allschwil, Switzerland).
For the studies performed on frozen tissue sections, mice were anesthetized and the tissues were fixed by vascular perfusion of 1% paraformaldehyde in PBS pH 7.4 for 4 minutes under 120 mm/Hg of pressure. GC muscles were harvested, post fixed in 0.5% paraformaldehyde in PBS for 2 hours, cryo-protected in 30% sucrose in PBS overnight at 4° C., embedded in OCT compound (CellPath, Newtown, Powys, UK), frozen in freezing isopentane and cryosectioned. Tissue sections (30 μm) were stained with Hematoxylin and eosin (H&E) and in addition, the gel biocompatibility was examined with Masson trichrome staining (Réactifs RAL, Martillac, France), performed according to manufacturer's instructions. For immunofluorescent staining of neighboring 30 μm thick longitudinal cryosections, the sections were blocked with PBS 0.1% triton supplemented with 5% normal goat or donkey serum and 2% BSA (all reagents from Sigma-Aldrich Chemie GmbH, Steinheim, Germany) for 1 hour. The slides were then incubated for 1.5 hour at room temperature with the following primary antibodies and dilutions: rat anti-mouse PECAM-1 (clone MEC 13.3, BD Biosciences, Basel, Switzerland) at 1:100 or hamster monoclonal 300 anti-mouse CD31 (clone 2H8, Millipore, Merck, Germany) at 1:200; mouse anti-mouse/human a-SMA (clone 1A4, MP Biomedicals, Basel, Switzerland) at 1:400, anti-mouse NG2 (Chemicon International, Hampshire, UK) at 1:200; rabbit anti-Ki67 (Abcam, Cambridge, UK) at moo, rat monoclonal anti-CD11b (clone M1/70, Abcam, Cambridge, UK) at moo, rat anti-mouse CD45 (PE conjugated, clone 30 F11, BD Biosciences, Basel, Switzerland) at 1:400. Negative controls lacking primary antibody were always performed. Sections were rinsed in PBS 0.1% triton and then incubated for 1.5 hour at room temperature with fluorescently labeled secondary antibodies (Invitrogen, Basel, Switzerland) diluted at 1:200. The slides were then rinsed and mounted.
Piezo1 staining immunohistochemistry experiments were performed on Ventana Discovery Ultra instrument (Roche Diagnostics, Manheim, Germany) by using the procedure RUO Discovery Universal instead. Cryosections were fixed for 12 minutes with 4% paraformaldehyde followed by 1 hour incubation at 37° C. with rat anti-CD11b (1:100) and 32 minutes incubation at 37° C. with a fluorescently labeled anti rat secondary antibody used at 1:200 (Invitrogen, Basel, Switzerland). Next, after an antibody denaturation step, sections were pre-treated for 16 minutes with Cell Conditioning Solution (CC1) (Roche Diagnostics, Mannheim). Rabbit anti Piezo1 (Proteintech, Manchester, UK) diluted at 1:500 was then incubated for 1 hour at 37° C. and detected with the secondary antibody (ImmPRESS reagent kit peroxidase anti-rabbit Ig MP-7401, Vector) applied manually (200 μl) for 32 minutes.
Discovery Rhodamine (Roche Diagnostics, Mannheim) applied for 12 minutes was used for the detection. To study vessel perfusion, 100 μg of biotinylated Lycopersicon esculentum (tomato) lectin (Vector Laboratories, Burlingame, Calif.) was dissolved in 100 μl, which binds the luminal surface of all blood vessels, and injected intravenously through the femoral vein. After four minutes the thoracic cavity was opened and the tissues were fixed by perfusing the animal with 1% paraldehyde and leg muscle were collected and processed as described above. Fluorescently labeled Streptavidin (eBioscience, Vienna, Austria) at 1:200 was used to visualize the perfused vasculature. Frozen sections were mounted with Faramount Aqueous Mounting Medium (Dako, Agilent Technologies, Basel, Switzerland), and fluorescence images were taken with 40× objectives on a Carl Zeiss LSM710 3-laser scanning confocal microscope (Carl Zeiss, Feldbach, Switzerland) or with a 20× objective on an Olympus BX61 microscope (Olympus, Volketswil, Switzerland). All Image analysis were performed with either Cell Sense software (Olympus, Volketswil, Switzerland) or Imaris 7.6.5 software (Bitplane, Zürich, Switzerland) on fluorescence images acquired with a 20× objective on an Olympus BX61 microscope or with a 40× objective on a Carl Zeiss LSM710 3-laser scanning confocal microscope.
The quantification of vessel length density (VLD) and vessel perfusion was performed on sections of leg muscles harvested after intravascular staining with biotinylated lectin and fluorescently labeled streptavidin, as described above. After co-staining with a fluorescent anti-CD31 antibody, VLD was measured on 6-10 randomly acquired fields per leg and 4 muscles per group (n=4) by tracing the total length of vessels in the fields and dividing it by the area of the fields. The total lengths of lectin-positive and CD31-positive vascular structures in each field were traced independently and the vessel perfusion index was calculated as the ratio between the two values. Vascular segment length was also measured in all representative fields per muscles tracing the total length of vessels and dividing it for the number+1 of branching points. Vessel diameters were measured by overlaying a captured microscopic image with a square grid. Squares were chosen at random, and the diameter of each vessel (if any) in the center of selected squares was measured. Two to five hundred total vessel diameter measurements were obtained from 4 muscles 350 per each group (n=4). KI67+ endothelial cells (ECs) were quantified from the total number of ECs (260-890 total ECs were counted per condition at 7 weeks post gel implantation) in vascular structures visible in each of 3-5 fields, in each area of effect. 10 areas with a clear angiogenic effect were analyzed per group. The quantification of leukocytes (CD45) and monocyte (CD11b) were performed on 7 random areas per muscle (n=4) per group by counting them and normalizing to the absolute number of CD45+ and CD11b+ cells with area. (9000-1400 total CD45+ cells and 5000-6000 total CD11+ cells were counted per condition at 2 weeks post gel implantation). The quantification of Piezo1+/CD11b+ cells was performed on 7-10 random areas per muscle (n=4) after immunostaining for CD11b (700-800 total CD11+ cells were counted per condition at 2 weeks post gel implantation).
All Image measurements were performed with both Cell Sense software (Olympus Volketswil, Switzerland) and Imaris 7.6.5 software on fluorescence images acquired with a 20× objective on an Olympus BX61 microscope or with a 40× objective on a Carl Zeiss LSM710 3-laser scanning confocal microscope.
Peripheral Blood Mononuclear Cells (PBMCs) were isolated from 3 immune-deficient SCID CB.17 mice (Charles River Laboratories, Sulzfeld, Germany) and 3 human healthy donor using a density gradient technique (Histopaque-1077, Sigma-Aldrich Chemie GmbH, Steinheim, Germany). Briefly, after centrifugation, carefully aspirated PBMCs from the Ficoll-plasma interface were stained for APC-anti-human CD11b (clone ICRF44, BD Biosciences, Basel, Switzerland) at 1:100 or rat monoclonal anti-CD11b at 1:100 and anti-human Piezo1 (Abcam, Cambridge, UK) at 1:500. Fluorescently labeled secondary antibody to detect Piezo1 (Invitrogen, Basel, Switzerland) was used at 1:200. Samples were acquired by LSR Fortessa (BD Biosciences, Basel, Switzerland), 375 and data analyzed by FlowJo software (Tree Star, Ashland, Oreg., USA).
Data are presented as mean±standard error. The significance of differences was assessed with the GraphPad Prism 7.03 software (GraphPad Software). The normal distribution of all data sets was tested and, depending on the results, multiple comparisons were performed with the parametric 1-way analysis of variance (ANOVA) followed by the Sidak test for multiple comparisons, or with the non-parametric Kruskal-Wallis test followed by Dunn's post-test, while single comparisons were analyzed with the non-parametric Mann-Whitney test or the parametric unpaired t-test.
| Number | Date | Country | Kind |
|---|---|---|---|
| 18199955.8 | Oct 2018 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2019/077621 | 10/11/2019 | WO | 00 |
